Antonella Folgori

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.

Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.

Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates.

Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.

Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections.

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.

Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.

Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.

Induction and Maintenance of CX3CR1-Intermediate Peripheral Memory CD8 T Cells by Persistent Viruses and Vaccines.

Characterizing Hepatitis C Virus-Specific CD4 T Cells Following Viral-Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure.

A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.

Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans.

New viral vectors for infectious diseases and cancer.